These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
406 related articles for article (PubMed ID: 34030536)
1. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma. Wong JL; Rosenberg JE Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536 [TBL] [Abstract][Full Text] [Related]
2. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence. Khosravanian MJ; Mirzaei Y; Mer AH; Keyhani-Khankahdani M; Abdinia FS; Misamogooe F; Amirkhani Z; Bagheri N; Meyfour A; Jahandideh S; Barpour N; Nikmanesh Y; Shahsavarani H; Abdollahpour-Alitappeh M Life Sci; 2024 Sep; 352():122910. PubMed ID: 39002610 [TBL] [Abstract][Full Text] [Related]
3. [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma]. Klümper N; Eckstein M; Kunath F; Heidegger I; Becker C; Rausch S; Urologie; 2023 Nov; 62(11):1193-1199. PubMed ID: 37658236 [TBL] [Abstract][Full Text] [Related]
4. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma. Halford Z; Anderson MK; Clark MD Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172 [TBL] [Abstract][Full Text] [Related]
5. An iodine‑labelled Antibody-drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma. Ren Y; Liu T; Li S; Ma X; Xia L; Wang P; Guo Q; Yao Y; Hou X; Sheng X; Zhu H; Yang Z Int J Pharm; 2024 Feb; 651():123756. PubMed ID: 38160990 [TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. Ungaro A; Tucci M; Audisio A; Di Prima L; Pisano C; Turco F; Delcuratolo MD; Di Maio M; Scagliotti GV; Buttigliero C Cells; 2022 Feb; 11(5):. PubMed ID: 35269424 [TBL] [Abstract][Full Text] [Related]
7. Nectin-4: a Novel Therapeutic Target for Skin Cancers. Hashimoto H; Tanaka Y; Murata M; Ito T Curr Treat Options Oncol; 2022 Apr; 23(4):578-593. PubMed ID: 35312963 [TBL] [Abstract][Full Text] [Related]
8. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors. Rigby M; Bennett G; Chen L; Mudd GE; Harrison H; Beswick PJ; Van Rietschoten K; Watcham SM; Scott HS; Brown AN; Park PU; Campbell C; Haines E; Lahdenranta J; Skynner MJ; Jeffrey P; Keen N; Lee K Mol Cancer Ther; 2022 Dec; 21(12):1747-1756. PubMed ID: 36112771 [TBL] [Abstract][Full Text] [Related]
9. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma. Mantia CM; Sonpavde G Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857 [TBL] [Abstract][Full Text] [Related]
10. The emerging role of antibody-drug conjugates in urothelial carcinoma. Lattanzi M; Rosenberg JE Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213 [TBL] [Abstract][Full Text] [Related]
11. Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer. Klümper N; Eckstein M Eur Urol Focus; 2024 Mar; 10(2):224-226. PubMed ID: 38631991 [TBL] [Abstract][Full Text] [Related]
12. Nectin-4: a Tumor Cell Target and Status of Inhibitor Development. Bouleftour W; Sargos P; Magne N Curr Oncol Rep; 2023 Mar; 25(3):181-188. PubMed ID: 36696077 [TBL] [Abstract][Full Text] [Related]
13. Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer. Weiten R; Bernhardt M; Niemann M; Kristiansen G; Grünwald V; Ritter M; Hölzel M; Eckstein M; Alajati A; Klümper N; Krausewitz P J Cell Mol Med; 2024 Jul; 28(14):e18572. PubMed ID: 39072867 [TBL] [Abstract][Full Text] [Related]
14. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma. McGregor BA; Sonpavde G Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130 [No Abstract] [Full Text] [Related]
15. Antibody-drug conjugates for urothelial carcinoma. Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845 [TBL] [Abstract][Full Text] [Related]
17. Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption. Hasegawa T; Oyama N; Kasamatsu H; Chino T; Taga M; Hasegawa M J Dermatol; 2022 Dec; 49(12):e453-e454. PubMed ID: 36052729 [No Abstract] [Full Text] [Related]
18. Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers. Zhou W; Fang P; Yu D; Ren H; You M; Yin L; Mei F; Zhu H; Wang Z; Xu H; Cao Y; Sun X; Xu X; Bi J; Wang J; Ma L; Wang X; Chen L; Zhang Y; Cen X; Zhu X; Lou L; Liu D; Tan X; Yang J; Meng T; Shen J Mol Cancer Ther; 2023 Aug; 22(8):913-925. PubMed ID: 37196158 [TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors. Tang M; Garg A; Bonate PL; Rosenberg JE; Matsangou M; Kadokura T; Yamada A; Choules M; Pavese J; Nagata M; Tenmizu D; Koibuchi A; Heo N; Wang L; Wojtkowski T; Hanley WD; Poondru S Clin Pharmacokinet; 2024 Apr; 63(4):423-438. PubMed ID: 38609704 [TBL] [Abstract][Full Text] [Related]
20. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]